Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | MME | P08473 | 2/20 | 0.55 |
| ▸ | ACE | P12821 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.50 |
| ▸ | CPA1 | P15085 | 1/20 | 0.49 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.49 |
| ▸ | ACP3 | P15309 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.45 |
| ▸ | PTPRA | P18433 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2684738 | 1.00 | CTNNB1 (0.61) | CTNNB1TDP1MMEACESMN1; SMN2 | |
| SCHEMBL1826710 | 1.00 | CTNNB1 (0.61) | CTNNB1TDP1MMEACESMN1; SMN2 | |
| SCHEMBL7272663 | 0.85 | CTNNB1 (0.75) | CTNNB1TDP1MMEACEHRH4 | |
| SCHEMBL11410876 | 0.84 | CTNNB1 (0.55) | CTNNB1TDP1MMEACECYP1A2 | |
| SCHEMBL6677809 | 0.84 | CTNNB1 (0.63) | CTNNB1TDP1MMEACEHRH4 | |
| SCHEMBL1244997 | 0.83 | CTNNB1 (0.55) | CTNNB1TDP1MMEACEHRH4 | |
| SCHEMBL27584168 | 0.83 | TDP1 (0.54) | CTNNB1TDP1MMEACECYP1A2 | |
| SCHEMBL660499 | 0.81 | CTNNB1 (0.59) | CTNNB1TDP1HRH4CYP1A2SLC1A3 | |
| SCHEMBL6898775 | 0.81 | CTNNB1 (0.59) | CTNNB1TDP1MMEACEHRH4 | |
| SCHEMBL93516 | 0.81 | CTNNB1 (0.59) | CTNNB1TDP1HRH4CYP1A2SLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11203565-B2 | Ester compound and PIN1 inhibitor, inflammatory disease therapeutic, and colon cancer therapeutic in which said ester compound is used | HIROSHIMA UNIVERSITY (JP) | 2021-12-21 | — | — | US | disclosed |
| US-9315792-B2 | Nitrilases, nucleic acids encoding them and methods for making and using them | BASF ENZYMES LLC (US) | 2016-04-19 | — | — | US | disclosed |
| US-9217164-B2 | Nitrilases, nucleic acids encoding them and methods for making and using them | BASF ENZYMES LLC (US) | 2015-12-22 | — | — | US | disclosed |
| EP-2327766-B1 | Nitrilases | BASF ENZYMES LLC (US) | 2015-12-02 | — | — | EP | disclosed |
| EP-2319919-B1 | Nitrilases | BASF ENZYMES LLC (US) | 2015-08-12 | — | — | EP | disclosed |
| EP-1576108-B1 | NITRILASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | BASF ENZYMES LLC (US) | 2015-07-08 | — | — | EP | disclosed |
| US-20150125928-A1 | NITRILASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | BASF ENZYMES LLC | 2015-05-07 | — | — | US | disclosed |
| EP-2327765-B1 | Nitrilases | BASF ENZYMES LLC (US) | 2015-04-01 | — | — | EP | disclosed |
| US-8906663-B2 | Nitrilases | VERENIUM CORPORATION (US) | 2014-12-09 | — | — | US | disclosed |
| US-8906663-B2 | Nitrilases | VERENIUM CORPORATION (US) | 2014-12-09 | — | — | US | disclosed |
| US-20100273659-A1 | Nitrilases, Nucleic Acids Encoding Them and Methods for Making and Using Them | VERENIUM CORPORATION (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100086986-A1 | Increased activity and stability at increased pH and temperature; making a chiral alpha -hydroxy acid molecule, a chiral amino acid molecule, a chiral beta -hydroxy acid molecule, or a chiral gamma-hydroxy acid molecule, from a molecule with a cyanohydrin moiety or an aminonitrile moiety | VERENIUM CORPORATION (US) | 2010-04-08 | — | — | US | disclosed |
| US-20100086986-A1 | Increased activity and stability at increased pH and temperature; making a chiral alpha -hydroxy acid molecule, a chiral amino acid molecule, a chiral beta -hydroxy acid molecule, or a chiral gamma-hydroxy acid molecule, from a molecule with a cyanohydrin moiety or an aminonitrile moiety | VERENIUM CORPORATION (US) | 2010-04-08 | — | — | US | disclosed |
| US-7651849-B2 | Increased activity and stability at increased pH and temperature | VERENIUM CORPORATION | 2010-01-26 | — | — | US | disclosed |
| US-7651849-B2 | Increased activity and stability at increased pH and temperature | VERENIUM CORPORATION | 2010-01-26 | — | — | US | disclosed |
| US-20090176976-A1 | Increased activity and stability at increased pH and temperature | VERENIUM CORPORATION | 2009-07-09 | — | — | US | disclosed |
| US-20090176976-A1 | Increased activity and stability at increased pH and temperature | VERENIUM CORPORATION | 2009-07-09 | — | — | US | disclosed |
| US-7521216-B2 | Nitrilases and methods for making and using them | VERENIUM CORPORATION (US) | 2009-04-21 | — | — | US | disclosed |
| US-7521216-B2 | Nitrilases and methods for making and using them | VERENIUM CORPORATION (US) | 2009-04-21 | — | — | US | disclosed |
| EP-2039762-A2 | Nitralases | Verenium Corporation (US) | 2009-03-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100086986-A1 | Increased activity and stability at increased pH and temperature; making a chiral alpha -hydroxy acid molecule, a chiral amino acid molecule, a chiral beta -hydroxy acid molecule, or a chiral gamma-hydroxy acid molecule, from a molecule with a cyanohydrin moiety or an aminonitrile moiety | ASPH, AHSA1, DNPH1 | CTNNB1 1673/4885TDP1 241/4885MME 84/4885 |
| US-11203565-B2 | Ester compound and PIN1 inhibitor, inflammatory disease therapeutic, and colon cancer therapeutic in which said ester compound is used | PIN1, APC, GSKIP | CTNNB1 1036/4885TDP1 3790/4885MME 2733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.